Title: Cancer Vaccines and Oncology

Biography:

Robens Molaire Saintil was born in Haiti. He lives there until June 1993.He starts to study medicine in the Dominican Republic in 1994. He is a medical doctor since 2000. He is Dominican since 2001. He did residence in internal medicine in Padre Billini Hospital from 2003 to 2006 and clinical Oncology in Heriberto Pieter Oncology Institute from 2007 to 2010. The Dominican Republic. He has a master in hospital management in Madrid, Spain in 2014 to 2015, another master in pain in Spain in august 2020 to march 2022 and a PhD in nutritional Science at Atlantic International University of USA, but I don’t have this diplome for many reasons.  He had colorectal cancer from march 2021 to April 2022. Now he is in observation. To be update, he continues with MEDSCAPE and NCCN for continuing medical education since 2016 and has actually approximately 350 credits. Now, he works at a provincial hospital in Monte Plata in the field of internal medicine, Dominican Republic. He is very interested about investigations about this topic and hopes the scientists can early have good results for the patients’ treatment. 

Abstract

The future of cancer vaccines is very promising. Effectively, Immunotherapy and vaccines have revolutionized disease treatment and prevention. The idea of a cancer vaccine is to activate the immune system to pick out ways that the cancer is different from normal cells, recognize them as foreign and reject them. Some cancer vaccines have been approved for human use, either like prevention against infections agents associated with cancers, or like therapeutic vaccines used as immunotherapy agents to treat cancers.  Therapeutic cancer vaccines differ from preventive ones, and immunotherapy drugs differ from both types of vaccines. Cancer vaccines aim to eliminate tumor cells by stimulating and broadening T cell responses specific for those cells.

 Developing cancer vaccines is a field of many interests for scientists, but also with many challenges, like heterogeneity within and between cancer types, screening and identification of appropriate tumor specific antigens, the choice of vaccine delivery platforms.

In all these areas, we have achieved new advances and the vaccines for Covid-19 are new experiences for the field of cancer vaccines, what booted the interests of scientists for its development. In fact, researchers have long hoped to use mRNA vaccines, for a very different purpose, to treat cancer and mRNA-based cancer treatment vaccines have been tested in small trials for nearly a decade, with some promising early results. Too, we hope further advances in those areas to facilitate the development of effective novel cancer vaccines for our patients. The research is growing, but experts warn that widespread use of cancer vaccines is still years away. Nevertheless, they predict their use will become standard practice.